Generic Versions Of Blood Thinning Plavix Approved By FDA

Generic Versions Of Blood Thinning Plavix Approved By FDA

Editor's Choice
Main Category: Cardiovascular / Cardiology
Also Included In: Blood / Hematology;  Regulatory Affairs / Drug Approvals
Article Date: 20 May 2012 - 8:00 PDT

email to a friend   printer friendly   opinions   <!-- rate article

Patient / Public:

4 (1 votes)

Healthcare Prof:

Generic versions of blood-thinning medication - Plavix (clopidogrel bisulfate) - have been approved by the FDA (Food and Drug Administration). Clopidogrel bisulfate reduces the likelihood of blood platelets clumping together and forming clots in blood vessels, resulting in a lower risk of stroke and heart attack.

Clopidogrel is approved by the FDA for individuals who recently had a stroke or heart attack, as well as patients who have peripheral artery disease - partial or total blockage of an artery.

Keith Webber, Ph.D., deputy director of the Office of Pharmaceutical Science in the FDA's Center for Drug Evaluation and Research, said:

"For people who must manage chronic health conditions, having effective and affordable treatment options is important. The generic products approved today will expand those options for patients."

Clopidogrel might not be effective with some patients with genetic factors that cause the body to metabolize the medication differently. The FDA says that clopidogrel has a boxed warning alerting doctors about this.

Doctors can screen patients for the genetic factors that alter how clopidogrel is metabolized in the body.

Clopidogrel's efficacy can also be affected by some medications, such as the proton pump inhibitors esomeprazole (Nexium) and omeprazole (Prilosec). Patients on such drugs may continue with high heart attack and stroke risk if they take clopidogrel.

Generic versions of Plavix (clopidogrel) are now on the market

Clopidogrel is associated with a risk of bleeding, which may sometimes be severe and even deadly. Patients on this medication may bleed and bruise more easily - their likelihood of having nosebleeds are also greater. Individuals on clopidogrel who bleed may take longer than normal for the bleeding to stop.

Clopidogrel comes with a Patient Medication Guide, which includes key instructions on how to use it, as well as drug safety information.

The following companies have received FDA approval for 300 mg clopidogrel:

• Teva Pharmaceuticals
• Mylan Pharmaceuticals
• Gate Pharmaceuticals
• Dr. Reddy's Laboratories

The following companies have received FDA approval for 75 mg clopidogrel:

• Torrent Pharmaceuticals
• Teva Pharmaceuticals
• Sun Pharma
• Roxane Laboratories
• Mylan Pharmaceuticals
• Aurobindo Pharma
• Apotex Corporation

The FDA emphasizes that generic and brand-name drugs have to undergo the same stringent requirements before they appear on pharmacy shelves. Brand-name and generic drugs that are FDA-approved have identical strengths and levels of quality, the Agency added.

Written by Christian Nordqvist

Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today

• Additional
• References
• Citations

Please use one of the following formats to cite this article in your essay, paper or report:

MLA

---

APA

---

Please note: If no author information is provided, the source is cited instead.

---

Add Your Opinion On This Article

'Generic Versions Of Blood Thinning Plavix Approved By FDA'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

Privacy Policy | Terms and Conditions

MediLexicon International Ltd
Bexhill-on-Sea, United Kingdom
MediLexicon International Ltd © 2004-2012 All rights reserved.
MNT (logo) is the registered EU trade mark of MediLexicon Int. Limited.

back to top | home | privacy policy

MediLexicon International Ltd
Bexhill-on-Sea, United Kingdom
MediLexicon International Ltd © 2004-2012 All rights reserved.
MNT (logo) is the registered EU trade mark of MediLexicon Int. Limited.